ES2149361T3 - Vacuna viva modificada contra el brsv, mejorada. - Google Patents

Vacuna viva modificada contra el brsv, mejorada.

Info

Publication number
ES2149361T3
ES2149361T3 ES95918442T ES95918442T ES2149361T3 ES 2149361 T3 ES2149361 T3 ES 2149361T3 ES 95918442 T ES95918442 T ES 95918442T ES 95918442 T ES95918442 T ES 95918442T ES 2149361 T3 ES2149361 T3 ES 2149361T3
Authority
ES
Spain
Prior art keywords
brsv
adjuvant
improved
immunity
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918442T
Other languages
English (en)
Inventor
Hsien-Jue Chu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2149361T3 publication Critical patent/ES2149361T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION PROPORCIONA UNA COMPOSICION DE VACUNA BRSV MEJORADA, QUE PROPORCIONA VENTAJOSAMENTE INMUNIDAD CONTRA LA INFECCION DESPUES DE UNA SOLA ADMINISTRACION. LA COMPOSICION INCLUYE UN VIRUS BRS VIVO ALTERADO Y UN ADYUVANTE, QUE PROPORCIONAN CONJUNTAMENTE INMUNIDAD FRENTE A LA INFECCION POR BRSV DESPUES DE UNA SOLA ADMINISTRACION, CONSIGUEN UNA RESPUESTA INMUNE ESPECIFICA A BRSV E INCLUYEN INMUNIDAD MEDIADA CELULARMENTE E INMUNIDAD LOCAL ( SECRECION IGA). EN LA VERSION PREFERIDA, EL VIRUS BRS ES DE LA VARIEDAD 375, Y EL ADYUVANTE INCLUYE UN HIDROCARBONO DE TURPINA INSATURADO, PREFERIBLEMENTE SECUALENO O SECUALANO, Y UN COPOLIMERO EN BLOQUE DE POLIOXIPROPILENO-POLIXIETILENO, MAS ESPECIFICAMENTE UNO EN EL QUE EL COPOLIMERO TENGA UN COMPONENTE POLIOXIPROPILENO (POP) CON UN PESO MOLECULAR MEDIO COMPRENDIDO ENTRE 3250 Y 4000 , SUPONIENDO EL COMPONENTE DE POLIOXIETILENO (POE) ENTRE UN 10-20% DE LA MOLECULA TOTAL. EL ADYUVANTE PUEDE INCLUIR OPCIONALMENTE UN SURFACTANTE, PREFERIBLEMENTE UN MONOOLEATO DE POLIOXIETILENESORBITANO.
ES95918442T 1994-05-10 1995-05-08 Vacuna viva modificada contra el brsv, mejorada. Expired - Lifetime ES2149361T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24037394A 1994-05-10 1994-05-10

Publications (1)

Publication Number Publication Date
ES2149361T3 true ES2149361T3 (es) 2000-11-01

Family

ID=22906268

Family Applications (3)

Application Number Title Priority Date Filing Date
ES95918442T Expired - Lifetime ES2149361T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el brsv, mejorada.
ES07008378T Expired - Lifetime ES2429401T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el BRSV, mejorada
ES99115633T Expired - Lifetime ES2287997T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el brsv mejorada.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES07008378T Expired - Lifetime ES2429401T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el BRSV, mejorada
ES99115633T Expired - Lifetime ES2287997T3 (es) 1994-05-10 1995-05-08 Vacuna viva modificada contra el brsv mejorada.

Country Status (19)

Country Link
US (2) US5733555A (es)
EP (4) EP1844791A1 (es)
JP (3) JP3993230B2 (es)
KR (1) KR100374434B1 (es)
CN (1) CN1268393C (es)
AT (2) ATE195255T1 (es)
AU (1) AU711350B2 (es)
BR (1) BR9507717A (es)
CA (1) CA2189979C (es)
DE (2) DE69518316T2 (es)
DK (2) DK0759780T3 (es)
ES (3) ES2149361T3 (es)
GR (1) GR3034402T3 (es)
MY (1) MY111829A (es)
NZ (1) NZ285324A (es)
PT (3) PT759780E (es)
SI (2) SI0968722T1 (es)
WO (1) WO1995030437A1 (es)
ZA (1) ZA953703B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
EP0679088B1 (en) * 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
CA2136677A1 (en) * 1993-12-29 1995-06-30 Intervet, Inc. Method of intranasally administering to bovines a trivalent vaccine containing modified live ibrv, pl3v and brsv
ATE416755T1 (de) * 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
PT759780E (pt) * 1994-05-10 2001-01-31 American Home Prod Vacina melhorada de vsrb vivo modificado
MX9605717A (es) * 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
DK0784486T3 (da) * 1994-10-05 2006-08-14 Univ Vanderbilt Interleukin-12 som en adjuvans til Paramyxoviridae-vacciner
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6908618B2 (en) 1997-11-10 2005-06-21 University Of Maryland Production of novel bovine respiratory syncytial viruses from cDNAs
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
TW440845B (en) 1999-08-11 2001-06-16 Ibm Method and system for programming FPGAs on PC-cards without additional hardware
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
BR0209482A (pt) 2001-05-10 2007-01-02 Wyeth Corp composição e método para aumento da densidade celular em culturas de células infectadas com lentivìrus
WO2003003941A2 (en) 2001-07-02 2003-01-16 Pfizer Products Inc. One dose vaccination with mycoplasma hyopneumoniae
HU228690B1 (en) 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
RS20050177A (sr) * 2002-08-26 2007-06-04 Pfizer Products Inc., Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke
EP1697505A1 (en) * 2003-12-23 2006-09-06 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8097288B1 (en) * 2008-04-16 2012-01-17 Pom Wonderful, Llc Composition and method for providing nutritional immunology for production animals
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
US20070031450A1 (en) * 2005-08-04 2007-02-08 Wyeth Stabilizers for veterinary vaccines
EP1968630B1 (en) 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
EP1911836A1 (en) * 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
EP2859900A1 (en) * 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
JP5200223B2 (ja) * 2006-12-15 2013-06-05 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２抗原によるブタの処置
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR20100113582A (ko) * 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
AR084358A1 (es) 2010-12-27 2013-05-08 Lilly Co Eli Composiciones y metodos para identificar y diferenciar componentes virales de vacunas multivalentes de la “fiebre de embarque” (complejo de enfermedad respiratoria bovina (brdc))
WO2012092053A1 (en) * 2010-12-27 2012-07-05 Eli Lilly And Company Bovine viral diarrhea virus type 1b vaccine compositions and methods
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
EP3049106A1 (en) 2013-09-25 2016-08-03 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
BR112022009082A2 (pt) * 2019-11-18 2022-07-26 Elanco Us Inc Bolo liofilizado em frasco de parede reta
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8301996A (nl) * 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
PT759780E (pt) * 1994-05-10 2001-01-31 American Home Prod Vacina melhorada de vsrb vivo modificado

Also Published As

Publication number Publication date
EP1844791A1 (en) 2007-10-17
WO1995030437A1 (en) 1995-11-16
CN1152878A (zh) 1997-06-25
PT1820512E (pt) 2013-10-09
GR3034402T3 (en) 2000-12-29
AU711350B2 (en) 1999-10-14
US5733555A (en) 1998-03-31
US5958423A (en) 1999-09-28
EP0759780B1 (en) 2000-08-09
CA2189979A1 (en) 1995-11-16
ES2429401T3 (es) 2013-11-14
PT968722E (pt) 2007-09-06
DE69518316T2 (de) 2001-03-29
KR100374434B1 (ko) 2003-06-09
NZ285324A (en) 1998-08-26
EP0759780A1 (en) 1997-03-05
EP0968722B1 (en) 2007-06-20
AU2438795A (en) 1995-11-29
PT759780E (pt) 2001-01-31
JP2007137905A (ja) 2007-06-07
DE69535520D1 (de) 2007-08-02
EP1820512B1 (en) 2013-07-03
DK0968722T3 (da) 2007-09-24
DE69535520T2 (de) 2008-02-07
BR9507717A (pt) 1997-09-23
JP2011246489A (ja) 2011-12-08
CN1268393C (zh) 2006-08-09
EP0968722A1 (en) 2000-01-05
DK0759780T3 (da) 2000-11-13
ES2287997T3 (es) 2007-12-16
ATE195255T1 (de) 2000-08-15
EP1820512A1 (en) 2007-08-22
JPH10500113A (ja) 1998-01-06
DE69518316D1 (de) 2000-09-14
HK1024412A1 (en) 2000-10-13
KR970703166A (ko) 1997-07-03
MY111829A (en) 2001-01-31
JP3993230B2 (ja) 2007-10-17
CA2189979C (en) 2011-04-19
SI0759780T1 (en) 2000-12-31
SI0968722T1 (sl) 2007-10-31
ATE365049T1 (de) 2007-07-15
ZA953703B (en) 1996-01-10

Similar Documents

Publication Publication Date Title
ES2149361T3 (es) Vacuna viva modificada contra el brsv, mejorada.
ME00569A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
ME00570A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
DE122010000042I1 (de) Solubilisierung von capsulären Polysacchariden
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
BRPI9911870B8 (pt) vacina de parvovírus e circovírus de suíno
DK0865297T3 (da) Vaccinesammensætninger til intranasal administration omfattende chitosan og anvendelsen deraf
ES2192582T3 (es) Composicion de vaccineo, conteniendo quitina, parcialmente deacetilado.
HUP0100058A1 (hu) LTB Adjuvánst tartalmazó vakcinák
DK0654086T3 (da) Vacciner mod Aujeszky's sygdom og andre dyresygdomme indeholdende mutanter af pseudo-rabies-virus
NO20023935L (no) Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
ATE182270T1 (de) Mukosale verabreichung von pneumokokken-antigenen
DE60031243D1 (de) Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease
MX9605503A (es) Vacuna mejorada de virus sincitial respiratorio debovino (brsv) vivo, modificado.
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis
UA49450A (uk) Вакцина інактивована рекомбінантна проти інфекційного ринотрахеїту великої рогатої худоби

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759780

Country of ref document: ES